🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Qiagen CEO quits amid genetic sequencing U-turn, shares tumble

Published 10/08/2019, 06:27 AM
Updated 10/08/2019, 06:31 AM
Qiagen CEO quits amid genetic sequencing U-turn, shares tumble
QIA
-
ILMN
-

FRANKFURT (Reuters) - Qiagen's (DE:QIA) longtime CEO Peer Schatz resigned after the German genetic testing company disclosed a reversal of its genome sequencing strategy and a slump in its Chinese business, sending its shares tumbling 20%.

In a surprise announcement late on Tuesday, the maker of diagnostic kits for cancer and tuberculosis said it would stop developing its next-generation genome sequencing machines and instead collaborate with industry leader Illumina (O:ILMN).

For the third quarter, Qiagen cut its forecast for sales growth, adjusted for currency swings, to about 3%, down from a previous outlook of 4%-5%, with its China business turning out significantly weaker than expected.

It expected to report adjusted third-quarter earning-per-share of $0.35-0.36, in line with its previous forecast.

Qiagen plans to take a pre-tax restructuring charge of about $260-$265 million, mainly to write down assets linked to the development of next-generation sequencing (NGS) instruments.

It also cited an overhaul of its global manufacturing network and possible job cuts for the writedown.

The company said Thierry Bernard, the head of the group's molecular diagnostics business, would now take over as interim boss until a permanent CEO was found.

Shares plunged 20% to 23.47 euros at 0848 GMT, with the group losing close to 1.4 billion euros ($1.54 billion) in market value, after already shedding about 17% over the previous three months.

"The fall from grace of Qiagen shares since June suggests that the market was already positioning for an unfavorable Q3, but the CEO's departure will come as a surprise," said Berenberg analyst Scott Bardo, adding the business nevertheless held the promise of attractive underlying growth.

Qiagen's core work includes making diagnostics kits that test for a single genetic mutation to help decide on treatment. But in recent years the company has developed into a smaller NGS player, where a wider range or all genes are sequenced.

As part of a 15-year collaboration deal with NGS pioneer Illumina (O:ILMN), Qiagen will rely on its genetic diagnostic products running on its new partner's hardware.

Schatz, who will become a special adviser to the supervisory board, had been with the company for 27 years. Since he started as finance chief in 1993, Qiagen has grown from $2 million in annual revenues to $1.5 billion in 2018.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.